ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma : Episode 17

Opinion

Video

April 19, 2024

Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.

EP: 1.First-Line Treatments for Advanced Clear Cell RCC

EP: 2.Long-Term Follow-Up from CheckMate 214 in Advanced RCC

EP: 3.CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

EP: 4.Recent Subgroup Analyses from the CLEAR study in Advanced RCC

EP: 5.LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

EP: 6.Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

EP: 7.CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

EP: 8.Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

EP: 9.LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

EP: 10.Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

EP: 11.CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

EP: 12.Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

EP: 13.Clinical Insights on Belzutifan in Advanced RCC

EP: 14.Overview of Non–Clear Cell RCC

EP: 15.TKI Monotherapy Data in Non–Clear Cell RCC

EP: 16.KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

EP: 17.Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

EP: 18.Future Perspectives and Unmet Needs in Renal Cell Carcinoma

Related Videos

3 experts are featured in this series.

2 experts in this video

2 experts in this video

2 experts in this video

2 experts in this video

Related Content

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Latest Conference Coverage

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.